Pyrifazimine

DB18898InvestigationalSmall molecule

Pyrifazimine is under investigation in clinical trial NCT04670120 (Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)).

Chemical structure of Pyrifazimine
Formula / weight
C32H30F3N5O3 · 589.619 g/mol (avg)
Also known as
2-PHENAZINAMINE, 3,5-DIHYDRO-3-((4-METHOXYCYCLOHEXYL)IMINO)-N-(2-METHOXY-3-PYRIDINYL)-5-(4-(TRIFLUOROMETHOXY)PHENYL)-
Code names
TBI-166

Resolves to

Compound
UNIITY9R7N6MS5CAS1353734-12-9
Structure
InChIKeyGUSGYHIQYWRCQO-UHFFFAOYSA-NSMILESCOC1CCC(CC1)N=C1C=C2N(C3=CC=C(OC(F)(F)F)C=C3)C3=CC=CC=C3N=C2C=C1NC1=CC=CN=C1OC
Transporters
F5H094SLCO1B3-SLCO1B7

What you can answer from here — as of August 16, 2026

1TransporterSubstrate / inhibitor direction, not just membership
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Pyrifazimine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In